Saturday 17 October 2026
Export KROS’s income statement to Excel — free account
Keros Therapeutics, Inc.
KROS Healthcare Biotechnology
In the quarter to June 2026, revenue fell 99.8%, EPS fell 90.8% and free cash flow grew 32.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
10.66
0.44
−3.96%
Follow KROS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
10.43% | 19.90% | (16.79%) | (17.16%) | |
Piotroski F-Score |
7 | 6 | 4 | — | |
| 9.75% | 18.24% | (15.53%) | (15.92%) | ||
ROIC |
269.50% | 268.69% | (1,668.70%) | (1,345.30%) | |
Return on Tangible Assets |
9.21% | 29.07% | (30.22%) | (32.18%) | |
Average Days of Receivables |
5.17 | 8.70 | 29.15 | 0.00 | |
Free Cash Flow per Share |
2.14 | 2.85 | (2.97) | (2.45) | |
Free Cash Flow |
87.08 | 105.95 | (58.25) | (48.49) | |
Capital Expenditures |
(1.71) | (1.55) | (1.06) | (0.49) | |
| Other line items | |||||
Cash ROIC |
6.23% | 17.94% | (10.27%) | (9.33%) | |
Accounts Receivable Turnover |
127.17 | 57.03 | 3.33 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.04) | (0.05) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
63.78% | 53.12% | 292.42% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
18.55% | 19.20% | 140.13% | 0.00% | |
Share Based Compensation of Revenue |
12.40% | 11.76% | 78.45% | 0.00% | |
Operating CF/Net income |
1.38 | 1.24 | 0.67 | 0.58 | |
Depreciation/Fixed assets |
0.32 | 0.35 | 0.40 | 0.43 | |
Capex/Depreciation |
(1.18) | (1.03) | (0.68) | (0.31) | |
Revenue per Share |
6.07 | 6.56 | 1.69 | 0.00 | |
Operating CF per Share |
2.19 | 2.89 | (2.91) | (2.42) | |
Capex per Share |
(0.04) | (0.04) | (0.05) | (0.02) | |
Capex to Sales |
0.01 | 0.01 | 0.03 | 0.00 |
Columns are period end dates